Regulation of human IL12/IL23 responsiveness by IL12RB1
IL12RB1 对人类 IL12/IL23 反应性的调节
基本信息
- 批准号:9751475
- 负责人:
- 金额:$ 37.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-25 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffinityAlternative SplicingAntibiotic TherapyAutoimmunityBacteriaBindingBiochemicalBiological AssayCause of DeathCell Differentiation processCell NucleusCell surfaceCellsChemosensitizationComplexCytokine ReceptorsDataDiseaseDisulfidesDominant-Negative MutationEnvironmentExtracellular SpaceGenesGenetic Complementation TestGenetic TranscriptionHIVHumanIL12RB1 geneImmune responseImmunobiologyImmunologicsImmunologyInterleukin-12KnowledgeLinkLungMalignant NeoplasmsMessenger RNAMethodsModelingMolecular BiologyMolecular ChaperonesMusMycobacterium tuberculosisNeutrophil InfiltrationPatientsPeripheral Blood Mononuclear CellPhosphorylationProductivityPropertyProtein IsoformsProteinsReagentReceptor SignalingRecurrenceRegulationReporterResearchResearch PersonnelResearch Project GrantsResistanceSignal PathwaySignal TransductionSiteSurfaceT cell responseT-LymphocyteTestingTranslatingTuberculosisbasecytokineextracellularhuman diseasehuman modelin vivoinnovationinterleukin-23macrophagenovelpathogenreceptorresponsetransmission processtuberculosis treatment
项目摘要
ABSTRACT
Tuberculosis (TB) is a human disease caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb). In
2015, TB ranked above HIV/AIDs as a leading cause of death worldwide. The gene IL12RB1 regulates human
resistance to TB by promoting cytokine (IL12/IL23)-dependent differentiation of naïve TH cells into TH1 and
TH17 effectors. TH1 and TH17 cells limit Mtb survival by activating Mtb-infected macrophages and recruiting
neutrophils to infected sites. It was established >20 years ago that IL12RB1 is transcribed and translated into
IL12Rβ1, a transmembrane receptor on the TH cell surface that binds IL12/IL23, and then complexes with
secondary receptors (IL12Rβ2, IL23R) to activate the intracellular signaling cascades that drive TH1/TH17
differentiation. However, we recently demonstrated that IL12RB1 is also transcribed and translated into a
second isoform (Isoform 2, or Iso2) that is a secreted potentiator of IL12/IL23 activity. The mechanism whereby
Iso2 potentiates IL12/IL23 activity is not known. Here, we propose a research project that will both fill important
gaps in our knowledge of IL12RB1 and determine the mechanism of Iso2 potentiation. This project is
significant since IL12RB1 regulates multiple immune responses including TB-resistance, and innovative
since it will establish a paradigm for how natural soluble cytokine receptors potentiate cytokine activity. This
project is also being pursued by an investigator with demonstrated independent expertise and productivity in
the field of IL12RB1-TB interactions, in an environment that is highly supportive of basic immunology
research. Finally, the methods and approach we use build on our demonstrated expertise in molecular
biology, immunology and the mouse TB model. There are two Specific Aims: (AIM 1) Determine the
biochemical mechanism that Isoform 2 enhances IL12/IL23 signaling; (AIM 2) Determine the immunological
mechanism that Isoform 2 increases TB resistance. At the end of our studies, we will have extended our basic
understanding of IL12RB1 immunobiology in the context of TB, as well as generated novel proteins with
potential use as an adjunct TB therapy. Since IL12RB1's influence extends beyond TB to also include
autoimmunity, cancer, and atopic disease, the mechanisms we identify are relevant to these other human
diseases.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Robinson其他文献
Richard Robinson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Robinson', 18)}}的其他基金
Regulation of human IL12/IL23 responsiveness by IL12RB1
IL12RB1 对人类 IL12/IL23 反应性的调节
- 批准号:
9925176 - 财政年份:2016
- 资助金额:
$ 37.99万 - 项目类别:
Regulation of human IL12/IL23 responsiveness by IL12RB1
IL12RB1 对人类 IL12/IL23 反应性的调节
- 批准号:
9761425 - 财政年份:2016
- 资助金额:
$ 37.99万 - 项目类别:
Neuronal and Developmental Regulation of Pacemaker Channels
起搏器通道的神经元和发育调节
- 批准号:
6740406 - 财政年份:2003
- 资助金额:
$ 37.99万 - 项目类别:
相似海外基金
Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
- 批准号:
488788 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Operating Grants
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
- 批准号:
10577186 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
- 批准号:
10717440 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
- 批准号:
10638347 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
- 批准号:
10749474 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
- 批准号:
10673458 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
- 批准号:
2884151 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
- 批准号:
10660668 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
- 批准号:
2239056 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
- 批准号:
468851650 - 财政年份:2022
- 资助金额:
$ 37.99万 - 项目类别:
Research Grants














{{item.name}}会员




